SCHEDULE: Vanguard Group Reports Zero Organon & Co Stake Post-Realignment

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Organon & Co following an internal realignment that disaggregated reporting responsibilities.

Summary

• The Vanguard Group filed an Amendment No. 5 to Schedule 13G for Organon & Co, common stock, CUSIP 68622V106.
• The filing reports 0% beneficial ownership of Organon & Co common stock by The Vanguard Group, with zero sole or shared voting and dispositive power.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538 (January 12, 1998).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It clarifies The Vanguard Group's reporting structure but provides no new information on Organon & Co's operational or financial performance.

Positives

• The filing clarifies the reporting structure for The Vanguard Group's holdings, enhancing transparency regarding which entities within the group hold specific securities.
• The realignment ensures compliance with SEC guidelines for beneficial ownership reporting by large institutional investors.

Negatives

• The Vanguard Group no longer directly reports beneficial ownership of Organon & Co, which may require investors to consult multiple filings from related entities to ascertain the aggregate holdings of the broader Vanguard organization.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding Organon & Co's business or financial performance. It focuses solely on The Vanguard Group's beneficial ownership reporting change.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that this filing reflects a common practice among large institutional investors like The Vanguard Group to adjust their reporting structures in response to internal organizational changes or regulatory interpretations. Such disaggregation can impact how aggregate institutional ownership is tracked, potentially requiring investors to look at multiple filings from related entities to get a complete picture of a fund family's total stake.

Comparison to Industry Standards

• This filing is a standard regulatory update for a large institutional investor, reflecting a change in its internal reporting structure rather than a change in investment strategy.
• The disaggregation of reporting by The Vanguard Group is consistent with practices allowed under SEC Release No. 34-39538 (January 12, 1998), which provides guidance for reporting beneficial ownership by parent holding companies and their subsidiaries.
• Similar reporting adjustments have been observed with other large asset managers that have complex organizational structures and multiple investment vehicles, ensuring compliance with evolving regulatory interpretations.

Stakeholder Impact

• Shareholders of Organon & Co: No direct operational impact on the company, but the change in Vanguard's reporting might alter how some data aggregators present institutional ownership, potentially requiring more granular research.
• Investors tracking Vanguard: Will need to be aware of the disaggregated reporting to obtain a comprehensive view of Vanguard's total holdings across all its entities.

Next Steps

• Investors interested in The Vanguard Group's total exposure to Organon & Co may need to review separate Schedule 13G filings from Vanguard's subsidiaries or business divisions that now report beneficial ownership independently.

Key Dates

Keywords

Vanguard Group, Organon & Co, Schedule 13G, Beneficial Ownership, SEC Filing, Investment Management, Institutional Investor, Realignment, Common Stock